Sterling Biotech Peer Comparison

NSE: STERLINBIO | BSE: 512299

₹0.70

₹0.00 (0.00%)

As on 05-Nov-2018IST

Market cap

₹21 Cr

Revenue (TTM)

₹457 Cr

P/E Ratio

--

P/B Ratio

-0

Div. Yield

0 %

Edit

	Sterling Biotech	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Market cap (₹ Cr)	21	31,870	26,208	25,861	25,299
Revenue (₹ Cr)	457	3,564	9,205	1,462	1,936
Net Profit (₹ Cr)	-19.29	414.00	-371.81	387.35	288.22
Net Margin (%)	-4.05	11.23	-3.93	26.01	14.79
RoE (%)	-2.17	8.38	-3.85	25.18	29.77
Price to Earnings	--	77.92	--	66.96	87.78
Price-To-Book	-0.01	6.33	3.27	14.99	18.85

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Sterling Biotech	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Operating Revenue	456.85	2,798.00	8,171.16	717.47	853.89
Total Income	476.71	2,881.00	8,372.30	724.97	872.39
Total Expenditure	390.66	2,759.00	7,000.65	588.98	699.30
EBITDA	66.19	39.00	1,170.51	128.49	154.59
Depreciation	15.27	223.00	740.57	16.06	38.97
EBIT	50.92	-184.00	429.94	112.43	115.62
Interest	0.72	305.00	448.49	5.94	31.26
Other Income	19.86	83.00	201.14	7.49	18.50
Exceptional Items	-76.99	-14.00	-62.79	-32.08	--
Profit before Tax	-6.93	-420.00	179.29	81.90	102.86
Provision for Tax	12.35	52.00	161.47	33.19	11.85
Profit after Tax	-19.29	-472.00	17.82	48.71	91.01

Liabilities (₹ Cr)

	Sterling Biotech	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Shareholder's Funds	879.42	3,359.00	7,911.37	674.00	385.00
Minority Interest	--	303.00	--	8.76	--
Non-Current Liabilities	-294.90	617.00	2,644.64	127.98	151.06
Current Liabilities	52.01	2,791.00	4,369.30	285.17	572.50
Total Liabilities	936.33	7,614.00	15,082.63	1,095.90	1,109.49

Assets (₹ Cr)

	Sterling Biotech	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Non-Current Assets	235.05	4,886.00	9,460.84	602.60	345.40
Current Assets	401.48	2,073.00	5,464.47	493.30	763.17
Total Assets	936.33	7,614.00	15,082.63	1,095.90	1,109.49
Total Debt*	10.82	2,112.00	4,558.86	216.65	396.41
Net Current Assets	349.47	-718.00	1,095.17	208.13	190.67
Contingent Liabilities	--	882.46	61.43	2.07	10.24

Cashflow (₹ Cr)

	Sterling Biotech	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Cash From Operating Activities	48.84	219.00	1,004.54	125.17	21.01
Cash Flow from Investing Activities	-98.28	-137.00	-434.01	-365.39	-68.51
Cash from Financing Activities	9.86	334.00	-422.36	239.36	43.55
Net Cash Inflow / Outflow	-39.58	416.00	148.17	-0.86	-3.95

Ratios

Profitability Ratios

	Sterling Biotech	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
ROCE (%)	-0.70	-2.15	5.07	11.81	19.36
ROE (%)	-2.17	-14.12	0.24	7.70	28.75
ROA (%)	-3.07	-6.67	0.12	5.23	9.80
EBIT Margin (%)	18.83	4.36	16.79	18.95	20.27
Net Margin (%)	-4.05	-16.38	0.21	6.72	10.43
Cash Profit Margin (%)	-0.88	-6.91	8.05	9.03	15.22

Growth Ratios

	Sterling Biotech	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Revenue Growth (%)	5.20	5.55	15.39	16.33	116.99
EBIT Growth (%)	25.02	-45.29	60.74	7.13	293.63
Net Profit Growth (%)	-100.32	23.99	109.56	-41.52	638.92
EPS Growth (%)	-100.32	22.55	108.83	-49.26	638.92
Book Value Growth (%)	-2.14	0.24	16.39	13.09	32.89

Valuation Ratios

	Sterling Biotech	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Price / Earnings	0.00	0.00	956.95	47.18	0.00
Price / Book Value	0.00	2.69	2.16	6.01	0.00
Dividend Yield (%)	--	0.00	0.09	0.27	--
EV/EBITDA	5.25	86.64	15.40	30.88	2.04
Market Cap (₹ Cr)	0.00	8,986.62	17,053.21	4,036.01	0.00

Solvency Ratios

	Sterling Biotech	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Debt to Equity	0.01	0.63	0.58	0.32	1.10
Short term debt to equity ratio	0.01	0.25	0.15	0.11	0.69
Current Ratio	7.72	0.74	1.25	1.73	1.33
Quick Ratio	5.36	0.51	0.75	1.18	0.81
Interest Coverage	-8.68	-0.38	1.40	14.79	4.29

Operating Efficiency Ratios

	Sterling Biotech	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Debtors to sales (%)	11.53	22.09	26.12	28.76	35.31
Asset Turnover	0.73	0.51	0.64	0.77	0.92
Receivable days	41.01	71.63	76.20	111.06	112.52
Inventory Days	87.13	65.71	74.72	70.18	99.96
Payable days	58.31	255.81	168.73	122.64	194.81
Cash Conversion Cycle	69.82	-118.47	-17.80	58.60	17.67

Annual
Quarterly